Navigation Links
Daiichi Sankyo Co., Ltd. Announces Acquisition of Biotech Firm U3 Pharma AG
Date:5/21/2008

his agent is currently in preparation for Phase 3 for osteoporosis, and in Phase 3 for bone metastases in patients with advanced breast cancer. Daiichi Sankyo also has the exclusive rights in Japan to develop and market nimotuzumab, or DE 766, which is licensed from CIMYM Biosciences. This is an oncologic agent in Phase 1 to treat advanced solid malignancies.

"Our acquisition of U3 Pharma is an ideal strategic fit for our oncology portfolio," said Takashi Shoda, President and CEO of Daiichi Sankyo Co., Ltd. "We currently have three human monoclonal antibodies in development. Additionally, in March, 2008, we announced that we were expanding our joint research venture with another German company, MorphoSys AG, for its advanced Human Combinatorial Antibody Library and its phage display technologies. One of our goals for Daiichi Sankyo is to increase our presence in novel therapeutics in the oncology arena."

"This transaction with Daiichi Sankyo represents an important and exciting milestone for U3 Pharma," said founder Professor Axel Ullrich of the Max Planck Institute of Biochemistry. "We look forward to working with our Daiichi Sankyo colleagues to advance our discovery pipeline and to collaborate on translating that pipeline into novel cancer therapies."

About Daiichi Sankyo Company, Limited

Daiichi Sankyo Company, Limited, established in 2005 after the merger of two leading century-old Japanese pharmaceutical companies, is a global pharmaceutical innovator, continuously generating innovative drugs that enrich the quality of life for patients around the world. The company uses its cumulative knowledge and expertise in the fields of cardiovascular disease, cancer, metabolic disorders, and infection as a foundation for developing an abundant product lineup and R&D pipeline. For more information, visit http://www.daiichisankyo.com.

*Herceptin(R) is a trademark of Genentech, Inc.
'/>"/>

SOURCE Daiichi Sankyo Co., Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. DAIICHI SANKYO EUROPE is Applying for Approval of its New Combination Product of Olmesartan and Amlodipin
2. Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration
3. Forest Laboratories, Inc. and Daiichi Sankyo, Inc. Announce the Termination of the AZOR Co-Promotion Agreement
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
6. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
7. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
8. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
9. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... ON , July 11, 2014 /CNW/ - Sunovion ... approved APTIOM TM (eslicarbazepine acetate) for use as ... seizures in patients with epilepsy who are not satisfactorily ... indicated for use in patients under 18 years of ... most common neurological disorders and according to Epilepsy Canada, ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 Deep ... Century Medicine Forum on ‘Commercialising Longevity Research’ and ... entrepreneurs to the London Bioscience Innovation Center for ... Foundation and Aging Analytics Ltd. The meeting highlighted ... in translational research for age-related disease, as well ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 OMICS Group’s ... techniques during 18-20 August, 2014 at Double Tree by ... the recent developments in Analytical & Bioanalytical research methods ... , Speaking on this occasion, Dr. Srinubabu Gedela, MD ... Acta conference is a remarkable one in bringing a ...
(Date:7/10/2014)...  Kainos Capital, a firm specializing in acquiring and ... has acquired the Slim-Fast brand from Unilever. Unilever will ... the transaction were not disclosed. Slim-Fast is ... markets ready-to-drink shakes, powders, bars and snacks to retail ... in the United Kingdom and ...
Breaking Biology Technology:Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Kainos Capital Acquires Slim-Fast From Unilever 2
... 29 BioSpecifics Technologies Corp. (Nasdaq: BSTC ), ... today that it was added to the Russell 3000 and ... markets on June 29, 2009. The Russell family of U.S. ... comprehensive representation of the investable U.S. equity market. , ...
... Inc. (Nasdaq: MITI ), a biopharmaceutical company ... inflammation and autoimmune diseases, today announced that it was ... the annual reconstitution of the Russell indexes, which occurred ... the Russell 3000 as an established benchmark for tracking ...
... manufacturing activities for ANX-530 NDA re-started , , SAN ... ANX ) today announced its plans for the remainder ... that closed earlier this month, ADVENTRX has re-started the final ... addition, the Company will continue to evaluate the data from ...
Cached Biology Technology:BioSpecifics Technologies Corp. Added to Russell 3000 and Russell 2000 Indexes 2Micromet Added to Russell 3000 Index 2Micromet Added to Russell 3000 Index 3Micromet Added to Russell 3000 Index 4ADVENTRX Pharmaceuticals Announces Plans for Remainder of 2009 2ADVENTRX Pharmaceuticals Announces Plans for Remainder of 2009 3
(Date:7/10/2014)... , July 7, 2014 According ... Research "Electronic Access Control Systems Market Global Forecast, Market ... the global Electronic Access Control systems market was valued ... to grow at a CAGR of 12.6% from 2014 ... 31,187.8 million in 2019. Browse the full ...
(Date:7/10/2014)... , July 9, 2014  Acuity Market Intelligence today released ... 2014 Edition" indicating that the global market for National Electronic ... 2013 to 2018. During this time, the number of National ... 3.5 billion. Asia , with its vast ... National eID cards issued, while Europe ...
(Date:7/10/2014)... belongs to the large, mainly tropical flowering plant family ... in the family rely on bees for their pollination. Only ... or vertebrates. The flowers of Axinaea appear in ... petals of the different species are pink, yellow, orange or ... the contrasting colours of their bulbous appendages. The pollination mechanism ...
Breaking Biology News(10 mins):Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 2Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 3Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 4Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 5National Electronic ID Programs Generate $54 Billion Between 2013 and 2018 with 3.5 Billion National eID Card Holders Worldwide 2Novel type of bird pollination mechanism discovered in South America 2
... MINNEAPOLIS, MN November 19, 2013 Data reported ... Ulm Project reinforce the positive influence of lifestyle factors ... heart disease and other health problems. Findings based on ... of obesity prevention and nutrition, specifically eating more fruits ...
... are located without much more than a sideways glance? Quite ... lead author of a study conducted at the Yerkes National ... Animal Cognition . The study finds that monkeys are ... Humans are able to locate, and even side-step, objects in ...
... Va. , Nov. 19, 2013   The Bensalem Township ... a new initiative in the field of DNA testing.  This ... will be the first of its kind in the country ... has its own local DNA database with over 6,000 DNA ...
Cached Biology News:Obesity and nutrition are keys to avoiding metabolic syndrome 2Monkeys can point to objects they do not report seeing 290 Minute DNA Results, A First Of Its Kind, Coming To Bensalem 2
Biotin or fluorescent labels can be attached and the stoichiometry of protein labeling determined....
...
These macrocarriers are for the biolistic PDS-1000 He and Hepta systems. Supplied as 500 macrocarriers....
...
Biology Products: